1 week Ago By ABMN Staff
Prudential Financial Inc. decreased its position in Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI – Free Report ) by 83.
8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,290 shares of the biopharmaceutical company’s stock after selling 22,193 shares during the quarter. Prudential Financial Inc.
’s holdings in Intra-Cellular Therapies were worth $358,000 at the end of the most recent quarter. Other large investors also recently bought and sold shares of the company. Vanguard Group Inc.
boosted its stake in shares of Intra-Cellular Therapies by 1.0% in the fourth quarter. Vanguard Group Inc.
now owns 9,721,360 shares of the biopharmaceutical company’s stock valued at $811,928,000 after purchasing an additional 93,107 shares during the period. LPL Financial LLC grew its stake in shares of Intra-Cellular Therapies by 38.7% during the fourth quarter.
LPL Financial LLC now owns 28,258 shares of the biopharmaceutical company’s stock valued at $2,360,000 after acquiring an additional 7,878 shares in the last quarter. Fox Run Management L.L.
C. acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at about $1,392,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $1,712,000.
Finally, Sei Investments Co. lifted its stake in shares of Intra-Cellular Therapies by 7.8% in the fourth quarter.
Sei Investments Co. now owns 197,806 shares of the biopharmaceutical company’s stock worth $16,520,000 after acquiring an additional 14,379 shares in the last quarter. Institutional investors and hedge funds own 92.
33% of the company’s stock. Wall Street Analysts Forecast Growth A number of equities analysts recently commented on ITCI shares. Piper Sandler reiterated a “neutral” rating and issued a $132.
00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th.
Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th.
Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company.
According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $106.23.
Intra-Cellular Therapies Price Performance Intra-Cellular Therapies stock opened at $131.87 on Friday. The business has a 50 day moving average of $130.
19 and a 200-day moving average of $103.76. The company has a market capitalization of $14.
05 billion, a P/E ratio of -151.57 and a beta of 0.69.
Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.
98. Intra-Cellular Therapies ( NASDAQ:ITCI – Get Free Report ) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.
16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08).
The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million.
Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%.
Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.
About Intra-Cellular Therapies ( Free Report ) Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. Featured Articles Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc.
( NASDAQ:ITCI – Free Report ). Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter .
.
